These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1804932)

  • 1. Comparison of class and subclass antibody response to live and UV-inactivated RSV administered intranasally in mice.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1991 Nov; 35(3):198-205. PubMed ID: 1804932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1991 Nov; 35(3):192-7. PubMed ID: 1804931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.
    Cano F; Plotnicky-Gilquin H; Nguyen TN; Liljeqvist S; Samuelson P; Bonnefoy J; Stâhl S; Robert A
    Vaccine; 2000 Jun; 18(24):2743-52. PubMed ID: 10781862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization.
    Okamoto Y; Tsutsumi H; Kumar NS; Ogra PL
    J Immunol; 1989 Apr; 142(7):2507-12. PubMed ID: 2926142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1990 Sep; 32(1):67-72. PubMed ID: 2243208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.
    Wagner DK; Muelenaer P; Henderson FW; Snyder MH; Reimer CB; Walsh EE; Anderson LJ; Nelson DL; Murphy BR
    J Clin Microbiol; 1989 Mar; 27(3):589-92. PubMed ID: 2715331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
    Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
    Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG; Crowe JE; Johnson TR; Tang YW; Graham BS
    J Infect Dis; 1999 Oct; 180(4):1324-7. PubMed ID: 10479165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.